Euclid Advisors’s Quest Diagnostics DGX Stock Holding History

Euclid Advisors’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-3,390	Closed	-$276K	–	133
2016 Q2	$276K	Buy	+3,390	New	+$258K	0.01%	429
2016 Q1	–	Sell	-39,108	Closed	-$2.78M	–	472
2015 Q4	$2.78M	Buy	+39,108	New	+$2.63M	0.09%	244
2015 Q3	–	Sell	-6,495	Closed	-$471K	–	279
2015 Q2	$471K	Sell	6,495 -97,595	-94%	-$7.21M	0.01%	401
2015 Q1	$8M	Buy	+104,090	New	+$7.45M	0.15%	157
2014 Q4	–	Sell	-77,120	Closed	-$4.68M	–	401
2014 Q3	$4.68M	Buy	77,120 +5,860	+8%	+$361K	0.03%	378
2014 Q2	$4.18M	Sell	71,260 -10,081	-12%	-$590K	0.03%	390
2014 Q1	$4.71M	Buy	81,341 +21,120	+35%	+$1.13M	0.04%	323
2013 Q4	$3.22M	Sell	60,221 -6,150	-9%	-$365K	0.03%	442
2013 Q3	$4.1M	Buy	66,371 +11,636	+21%	+$696K	0.04%	351
2013 Q2	$3.32M	Buy	+54,735	New	+$3.26M	0.04%	381

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Euclid Advisors's DGX Position: Q3 2016 in Review

Euclid Advisors sold out of Quest Diagnostics (DGX) in Q3 2016, closing a stake of 3,390 shares — an estimated $276K sold.

Euclid Advisors first reported a position in DGX in Q2 2013 and held it in 10 quarters. The position peaked at $8M in Q1 2015. 559 funds tracked by Wall St. Rank hold DGX as of Q3 2016.

Euclid Advisors reported no remaining Quest Diagnostics position as of Q3 2016 after selling out during the quarter.
Euclid Advisors sold 3,390 Quest Diagnostics shares in Q3 2016, an estimated $276K.
Euclid Advisors first reported a position in Quest Diagnostics in Q2 2013 and held it in 10 quarters.
Euclid Advisors's Quest Diagnostics position peaked at $8M in Q1 2015.
559 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2016.

Based on Euclid Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.